About matinas biopharma holdings inc - MTNB
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.
MTNB At a Glance
Matinas BioPharma Holdings, Inc.
1545 Route 206 South
Bedminster, New Jersey 07921-9999
| Phone | 1-908-484-8805 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -10,963,000.00 | |
| Sector | Health Technology | Employees | 4 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MTNB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.777 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.079 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 2.64 |
MTNB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,740,750.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MTNB Liquidity
| Current Ratio | 2.785 |
| Quick Ratio | 2.785 |
| Cash Ratio | 2.768 |
MTNB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -110.464 |
| Return on Equity | -176.538 |
| Return on Total Capital | -177.28 |
| Return on Invested Capital | -144.193 |
MTNB Capital Structure
| Total Debt to Total Equity | 28.033 |
| Total Debt to Total Capital | 21.895 |
| Total Debt to Total Assets | 18.785 |
| Long-Term Debt to Equity | 13.623 |
| Long-Term Debt to Total Capital | 10.64 |